CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...